CD9 and cancer: Tspan29 is sometimes employed as a biomarker for invasion and advanced stages of cancer, particularly in metastatic renal clear cell carcinoma, where it not only distinguishes tumor subtypes but also predicts the metastatic potential of renal cell carcinoma.